Skip to main content

Advertisement

SpringerLink
Log in

Radiomics on radiography predicts giant cell tumor histologic response to denosumab

  • Scientific Article
  • Published:
Skeletal Radiology Aims and scope Submit manuscript

Abstract

Objective

Denosumab is an established targeted systemic therapy for treatment of giant cell tumor of bone (GCTB). We sought to determine whether treatment response could be quantified from radiomics analysis of radiographs taken longitudinally during treatment.

Materials and methods

Pre- and post-treatment radiographs of 10 GCTB tumors from 10 patients demonstrating histologic response after treatment with denosumab were analyzed. Intensity- and texture-based radiomics features for each manually segmented tumor were calculated. Radiomics features were compared pre- and post-treatment in tumors.

Results

Mean intensity (p = 0.033) significantly increased while skewness (p = 0.028) significantly decreased after treatment. Post-treatment increases in fractal dimensions (p = 0.057) and abundance (p = 0.065) approached significance. A potential linear correlation in mean (p = 0.005; ΔMean = 0.022 * duration − 0.026) with treatment duration was observed.

Conclusion

Radiomics analysis of plain radiographs quantifies time-dependent matrix mineralization and trabecular reconstitution that mark positive response of giant cell tumors of bone to denosumab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Mendenhall WM, Zlotecki RA, Scarborough MT, Gibbs CP, Mendenhall NP. Giant cell tumor of bone. Am J Clin Oncol. 2006;29(1):96–9.

    Article  Google Scholar 

  2. Bini SA, Gill K, Johnston JO. Giant cell tumor of bone. Curettage and cement reconstruction. Clin Orthop Relat Res 1995(321):245–250.

  3. Garcia RA, Inwards CY, Unni KK. Benign bone tumors--recent developments. Semin Diagn Pathol. 2011;28(1):73–85.

    Article  Google Scholar 

  4. Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res. 2011;469(2):591–9.

    Article  Google Scholar 

  5. Trieb K, Bitzan P, Lang S, Dominkus M, Kotz R. Recurrence of curetted and bone-grafted giant-cell tumours with and without adjuvant phenol therapy. Eur J Surg Oncol. 2001;27(2):200–2.

    Article  CAS  Google Scholar 

  6. Branstetter DG, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res. 2012;18(16):4415–24.

    Article  CAS  Google Scholar 

  7. Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14(9):901–8.

    Article  CAS  Google Scholar 

  8. Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11(3):275–80.

    Article  CAS  Google Scholar 

  9. Demirsoy U, Karadogan M, Selek O, Anik Y, Aksu G, Muezzinoglu B, et al. Golden bullet-denosumab: early rapid response of metastatic giant cell tumor of the bone. J Pediatr Hematol Oncol. 2014;36(2):156–8.

    Article  CAS  Google Scholar 

  10. Karras NA, Polgreen LE, Ogilvie C, Manivel JC, Skubitz KM, Lipsitz E. Denosumab treatment of metastatic giant-cell tumor of bone in a 10-year-old girl. J Clin Oncol. 2013;31(12):e200–2.

    Article  Google Scholar 

  11. van der Heijden L, van de Sande MA, Hogendoorn PC, Gelderblom H, Dijkstra PD. Neoadjuvant denosumab for extensive giant cell tumor in os ischium: a case report. Acta Orthop. 2015;86(3):393–5.

    Article  Google Scholar 

  12. Yamagishi T, Kawashima H, Ogose A, Sasaki T, Hotta T, Inagawa S, et al. Disappearance of giant cells and presence of newly formed bone in the pulmonary metastasis of a sacral giant-cell tumor following denosumab treatment: a case report. Oncol Lett. 2016;11(1):243–6.

    Article  Google Scholar 

  13. Ueda T, Morioka H, Nishida Y, Kakunaga S, Tsuchiya H, Matsumoto Y, et al. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial. Ann Oncol. 2015;26(10):2149–54.

    Article  CAS  Google Scholar 

  14. Oguro S, Okuda S, Sugiura H, Matsumoto S, Sasaki A, Susa M, et al. Giant cell tumors of the bone: changes in image features after denosumab administration. Magn Reson Med Sci. 2018;17(4):325–30.

    Article  CAS  Google Scholar 

  15. Yi J, Lee YH, Kim SK, Kim SH, Song HT, Shin KH, et al. Response evaluation of giant-cell tumor of bone treated by denosumab: histogram and texture analysis of CT images. J Orthop Sci. 2018;23(3):570–7.

    Article  Google Scholar 

  16. Wojcik J, Rosenberg AE, Bredella MA, Choy E, Hornicek FJ, Nielsen GP, et al. Denosumab-treated giant cell tumor of bone exhibits morphologic overlap with malignant giant cell tumor of bone. Am J Surg Pathol. 2016;40(1):72–80.

    Article  Google Scholar 

  17. Haralick RM, Shanmugam K, Dinstein I. Textural features for image classification. IEEE Transactions on Systems, Man, and Cybernetics. 1973;SMC-3(6):610–21.

    Article  Google Scholar 

  18. Tolle C, McJunkin T, Gorsich D. An efficient implementation of the gliding box lacunarity algorithm. Physica D: Nonlinear Phenomena. 2008;237:306–15.

    Article  Google Scholar 

  19. Treffel M, Lardenois E, Larousserie F, Karanian M, Gomez-Brouchet A, Bouvier C, et al. Denosumab-treated giant cell tumors of bone: a clinicopathologic analysis of 35 cases from the French group of bone pathology. Am J Surg Pathol. 2020;44(1):1–10.

    Article  Google Scholar 

Download references

Acknowledgements

We thank Jared Mahan for his help in segmentation and processing of GCTB datasets.

Funding

Y.C. is funded by NEI fellowship 1F30EY027162.

Author information

Authors and Affiliations

  1. Miller School of Medicine, University of Miami, Miami, FL, USA

    Yu-Cherng Chang

  2. Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL, USA

    Radka Stoyanova

  3. Sylvester Comprehensive Cancer Center, Miami, FL, USA

    Radka Stoyanova, Juan A. Pretell-Mazzini & Ty Subhawong

  4. Department of Radiology, University of Miami Miller School of Medicine, Miami, FL, USA

    Sofia Danilova & Ty Subhawong

  5. Department of Orthopedics, University of Miami Miller School of Medicine, Miami, FL, USA

    Juan A. Pretell-Mazzini

  6. Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA

    Darcy A. Kerr

  7. Geisel School of Medicine at Dartmouth, Hanover, NH, USA

    Darcy A. Kerr

  8. Department of Medicine-Medical Oncology, University of Colorado Hospital, Aurora, CO, USA

    Breelyn A. Wilky

Authors
  1. Yu-Cherng Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Radka Stoyanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sofia Danilova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Juan A. Pretell-Mazzini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Darcy A. Kerr
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Breelyn A. Wilky
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ty Subhawong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ty Subhawong.

Ethics declarations

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Conflict of interest

T.S. has received support from AROG Pharmaceuticals, Inc.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chang, YC., Stoyanova, R., Danilova, S. et al. Radiomics on radiography predicts giant cell tumor histologic response to denosumab. Skeletal Radiol 50, 1881–1887 (2021). https://doi.org/10.1007/s00256-021-03752-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00256-021-03752-5

Keywords

Search

Navigation